Cargando…
Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson’s disease diagnosis is typically done when a sign...
Autores principales: | Mourtzi, Theodora, Kazanis, Ilias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165379/ https://www.ncbi.nlm.nih.gov/pubmed/35662194 http://dx.doi.org/10.4103/1673-5374.336137 |
Ejemplares similares
-
Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018) -
Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017) -
Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021) -
Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021) -
Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going
por: Mesnier, Jules, et al.
Publicado: (2022)